Parmax Pharma Ltd

Parmax Pharma Ltd has amended its Memorandum of Association (MOA) and adopted new Articles of Association (AOA) following approval at an Extraordinary General Meeting (EGM). The key amendment involves an increase in the company's authorized share capital from ₹6 Crores to ₹10 Crores, comprising 1 Crore equity shares of ₹10 each. The new Articles of Association have been adopted to align with the Companies Act, 2013, replacing the older ones based on the Companies Act, 1956. The amended MOA and AOA are available on the company's website.

Parmax Pharma Ltd has announced the closure of its trading window for designated persons. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from July 01, 2026, until 48 hours after the declaration of financial results for the quarter ending June 30, 2026. The specific date of the board meeting to consider these results will be communicated later.

Parmax Pharma Ltd has issued a corrigendum to its Extraordinary General Meeting (EGM) notice dated June 8, 2026. The corrigendum addresses two key points: a correction in the proposed status/category of Ms. Sheetal Hiren Doshi in the warrant allottees table from 'Promoter*' to 'Promoter Group*', and a rectification of the hyperlink for the Practicing Company Secretary's Certificate. The EGM is scheduled for July 2, 2026, to be held via Video Conferencing. This corrigendum, along with the original EGM notice and explanatory statement, will be available on the company's website.

Pradeep Ramniklal Gosalia has disposed of 3,00,000 equity shares of Parmax Pharma Limited, representing 8.02% of the total share capital. The transaction, which occurred on June 18, 2026, was executed via a Share Purchase Agreement between Rupa Sunil Shah and Abhay Chinubhai Shah. Prior to this sale, Gosalia held 3,02,714 shares (8.09% stake). Post-sale, his holding has reduced to 2,714 shares (0.07% stake). The total equity share capital of Parmax Pharma Limited remains unchanged at 37,41,300 shares.

Fedex Securities Pvt Ltd, acting as Manager to the Offer, has submitted a Draft Letter of Offer to BSE for the public shareholders of Parmax Pharma Ltd. This pertains to an open offer by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with several persons acting in concert (PACs), to acquire up to 23,46,250 equity shares. This represents 26.00% of the expanded voting capital of Parmax Pharma. The offer price is fixed at ₹42.80 per equity share. The open offer is being made in compliance with SEBI (SAST) Regulations, 2011.

Abhay Chinubhai Shah (PAC 8) acquired 2,49,394 equity shares, representing 2.76% of the total share capital, in Parmax Pharma Ltd through an off-market transaction on June 18, 2026. The acquisition was made from Pradeep Gosalia for an undisclosed price per share. Following this transaction, the total shareholding of acquirers and Persons Acting in Concert (PACs) in Parmax Pharma has increased to 27.20%. This disclosure is made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Rupa Sunil Shah, identified as PAC 5, has acquired 53,520 equity shares, representing 1.43% of the total share capital, in Parmax Pharma Limited through an off-market transaction on June 16, 2026. This acquisition was made in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. Following this transaction, the total shareholding of the acquirer and PACs has increased to 768,320 shares, constituting 20.54% of the company's total equity.

Parmax Pharma Ltd has announced an Extra-Ordinary General Meeting (EGM) to be held on July 2, 2026, via Video Conferencing. The primary agenda items include increasing the company's authorized share capital from ₹6 Crores to ₹10 Crores by creating an additional 40,00,000 equity shares, and altering the Memorandum of Association accordingly. Additionally, the EGM will consider adopting a new set of Articles of Association. The cut-off date for e-voting eligibility is June 25, 2026, with remote e-voting commencing on June 29 and concluding on July 1, 2026.

Parmax Pharma Ltd announced that Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with associated parties, are set to acquire majority control. This will be achieved through a combination of preferential allotment, a share purchase agreement (SPA) with existing promoters (Alkesh Mahasukhlal Gopani, Vipul Mahasukhlal Gopani, Pravina Mahasukh Gopani), and an open offer. The SPA involves the sale of shares at ₹35 per equity share. The acquisition is subject to statutory approvals. Separately, the company is issuing shares at ₹36.50 and convertible warrants at the same price.

Fedex Securities Pvt Ltd, acting as the Manager to the Offer, has announced a public offer for Parmax Pharma Limited. The offer aims to acquire up to 23,46,250 equity shares, representing 26.00% of the expanded voting share capital. This open offer is being made by Dhiren Chandulal Shah and Sunil Chinubhai Shah, along with several persons acting in concert (PACs), in compliance with SEBI (SAST) Regulations, 2011. The offer is intended to acquire a substantial number of equity shares, voting rights, and control of the target company.